Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
Completed · Phase 2 · Has a placebo group
Conditions studied: Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
In brief
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of the transplanted kidney.The pilot study compares the use of rituximab (Rituxan®) + site-specific standard immunosuppression to placebo + site-specific standard immunosuppression in the treatment of circulating anti-HLA antibodies in subjects who develop de novo anti-HLA antibodies between 3-36 months after transplant.
Key facts
- Study ID
- NCT00307125
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 757
- Starts
- 2006-03-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2015-03-23
Who can join
Age: 5 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama, Pediatric Nephrology — Birmingham, Alabama, United States
- University of Alabama — Birmingham, Alabama, United States
- University of California, San Francisco — San Francisco, California, United States
- University of Florida — Gainesville, Florida, United States
- University of Illinois — Chicago, Illinois, United States
- Northwestern University — Chicago, Illinois, United States
- University of Maryland — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- Children's Hospital Boston — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Saint Barnabas Medical Center — Livingston, New Jersey, United States
- Legacy Transplant Services — Portland, Oregon, United States
- Oregon Health Science University — Portland, Oregon, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- The Methodist Hospital — Houston, Texas, United States
- Children's Hospital and Regional Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.